Artemis for New Product Development Reduces Development Risks and Supports the Entire Pharmaceutical R & D Process
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--April 27, 2004-- Actelion Pharmaceuticals Ltd. (SWX:ATLN), one of Europe's fastest-growing companies, has selected the New Product Development (NPD) portfolio management solution from Artemis International Solutions Corp. (OTCBB:AMSI - News) to manage its pipeline of new pharmaceutical products that include Tracleer® and Zavesca®. Using Artemis NPD will help Actelion to manage its new product pipeline and detect successful candidates very early in the development process.
A pioneer in innovative science related to Endothelium, Actelion will use the Artemis NPD solution to:
Align and prioritize all products in its portfolio based on business strategy in order to maximize investment returns;
Maintain an optimum candidate pipeline portfolio by continuously reviewing, analyzing, simulating and restructuring the portfolio in response to change;
Identify products that are not aligned with business strategy and redistribute resource allocation amongst competing products to maximize performance;
Provide visibility and clarity on the product portfolio so that it can make rapid, informed real-time decisions.
The Artemis NPD solution is designed to manage all phases of Actelion's development process spanning both pre-clinical and clinical trial phases. In addition to the program and operational processes, Artemis NPD manages all costs, resources and anticipated benefits. Using configurable scorecards and product evaluation metrics, each product candidate can be rated by strict criteria and customized portfolio views provide current progress and status of the entire product pipeline. This approach helps Actelion to identify and assess risks and issues within the development process and detect problems at an early stage.
The Artemis solution also includes a range of reporting and scenario planning and simulation tools and automatically alerts management when product development efforts are approaching their resource and time limits. The results can be presented using a variety of different and personalized graphical views.
Ultimately the Artemis NPD solution provides the framework for optimal quality assurance, reduced time-to-market, maximum productivity and return on investment. With timely and accurate cost, schedule, risk and benefit information Actelion can manage its new product portfolio proactively and optimize the use of critical resources.
According to Miriam Halperin-Werli, head of business & science affairs for Actelion: "The results of the initial pilot convinced us that the Artemis solution will help us make informed decisions about whether to continue or stop the development of selected product candidates. We will continue to concentrate our resources on developing products that represent a genuine improvement for physicians, their patients and our company."
"We are delighted that Actelion has selected Artemis as its partner for managing its new product development portfolio," said Patrick Ternier, president and CEO of Artemis. "The pharmaceutical industry is a key focus for Artemis and we welcome Actelion to our growing list of pharmaceutical customers."
About Artemis International Solutions Corp.
Artemis International Solutions Corp. is one of the world's leading providers of investment planning and control solutions that help organizations execute strategy through effective portfolio and project management. Artemis has refined 30 years experience into a suite of solutions and packaged consulting services that address the specific needs of both industry and the public sector including, IT management, new product development, program management, fleet and asset management, outage management and detailed project management. With a global network covering 44 countries, Artemis is helping thousands of organizations to improve their business performance through better alignment of strategy, investment planning and project execution. For more information, visit www.aisc.com.
Forward Looking Statements
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This press release contains or may contain forward-looking statements such as statements regarding the Company's growth and profitability, growth strategy, liquidity and access to public markets, operating expense reduction and trends in the industry in which the Company operates. These forward-looking statements are based on current expectations and are subject to a number of risks, uncertainties and assumptions. Important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements are detailed in the documents filed by the Company with the Securities and Exchange Commission including but not limited to those contained under the Risk Factors section of Form 10-K for the year ended December 31, 2001. The Company assumes no obligation to update these forward-looking statements to reflect actual results, changes in risks, uncertainties or assumptions underlying or affecting such statements or for prospective events that may have a retroactive effect.
-------------------------------------------------------------------------------- Contact:
Lages & Associates for Artemis International
Kerry Fedro or Jennifer Tolkachev, 949-453-8080
kerry@lages.com/jennifer@lages.com
--------------------------------------------------------------------------------
Source: Artemis International
